Kailera Therapeutics (NASDAQ:KLRA) Hits New 12-Month Low – Should You Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price hit a new 52-week low on Friday . The stock traded as low as $18.69 and last traded at $18.83, with a volume of 260824 shares trading hands. The stock had previously closed at $19.54.

Analyst Ratings Changes

Several brokerages have recently weighed in on KLRA. TD Cowen started coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $57.00 target price on the stock. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Wall Street Zen lowered shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Leerink Partners started coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price target on the stock. Finally, Jefferies Financial Group started coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $42.75.

Kailera Therapeutics Stock Down 2.8%

Insider Buying and Selling

In other Kailera Therapeutics news, Director Andrew T. Kaplan purchased 8,398,438 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The stock was acquired at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the completion of the purchase, the director directly owned 26,255,581 shares in the company, valued at approximately $420,089,296. This represents a 47.03% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adam Koppel purchased 1,562,500 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were acquired at an average cost of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the purchase, the director owned 22,583,268 shares of the company’s stock, valued at $361,332,288. The trade was a 7.43% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 10,460,938 shares of company stock valued at $167,375,008 over the last ninety days.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.